Currently, there are 279.82M common shares owned by the public and among those 241.18M shares have been available to trade.
The company’s stock has a 5-day price change of -24.80% and -16.57% over the past three months. CORZ shares are trading -19.72% year to date (YTD), with the 12-month market performance up to 227.91% higher. It has a 12-month low price of $2.61 and touched a high of $18.63 over the same period. CORZ has an average intraday trading volume of 10.27 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -22.26%, -27.50%, and 5.40% respectively.
Institutional ownership of Core Scientific Inc (NASDAQ: CORZ) shares accounts for 62.51% of the company’s 279.82M shares outstanding.
It has a market capitalization of $3.15B and a beta (3y monthly) value of 6.76. The earnings-per-share (ttm) stands at -$5.45. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.70% over the week and 6.32% over the month.
Analysts forecast that Core Scientific Inc (CORZ) will achieve an EPS of 0.03 for the current quarter, 0.17 for the next quarter and 0.91 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.03 while analysts give the company a high EPS estimate of 0.03. Comparatively, EPS for the current quarter was -0.2 a year ago. Earnings per share for the fiscal year are expected to decrease by -513.38%, and 103.09% over the next financial year.
Looking at the support for the CORZ, a number of firms have released research notes about the stock. Keefe Bruyette stated their Outperform rating for the stock in a research note on January 27, 2025, with the firm’s price target at $22. Craig Hallum coverage for the Core Scientific Inc (CORZ) stock in a research note released on January 21, 2025 offered a Buy rating with a price target of $24. ROTH MKM was of a view on November 15, 2024 that the stock is Buy, while Jefferies gave the stock Buy rating on October 28, 2024, issuing a price target of $19. Macquarie on their part issued Outperform rating on September 25, 2024.
